Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation

Table 4 Profile of the immunosuppressive agents received according the type of Novel oral anticoagulants agent

NOAC	Calcineurin inhibitor used, n (%)					Total
	Advograf	Pyograf	Cycosporin	Sirolimus	None
Dabigatran 150 mg bid	2 (7.4)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4.8)
Dabigatran-low dose	1 (3.7)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.4)
Apixaban 5 mg bid	8 (29.6)	1 (25.0)	0 (0)	2 (50.0)	1 (50.0)	12 (28.6)
Apixaban-low dose	10 (37.0)	2 (50.0)	3 (60.0)	2 (50.0)	0 (0)	17 (40.5)
Rivaroxaban 20 mg/d	4 (14.8)	1 (25.0)	0 (0)	0 (0)	0 (0)	5 (11.9)
Rivaroxaban low dose	2 (7.4)	0 (0)	2 (40.0)	0 (0)	1 (50.0)	5 (11.9)

All patients also received prednisolone and mycophenolate mofetil. NOACs: Novel oral anticoagulants.